Skip to content

CARPEUS : Effect of Carvedilol on the portosystemic gradient as measured by endoscopic ultrasound

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-518302-41-00
Acronym
AOI 2023 POINCLOUX
Enrollment
30
Registered
2025-01-29
Start date
2025-04-16
Completion date
Unknown
Last updated
2025-08-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cirrhotic portal hypertension

Brief summary

Hemodynamic response (binary efficacy criterion) at one month, defined by a decrease of at least 10% in the echo-endoscopic portosystemic gradient compared to the baseline value measured at inclusion.

Detailed description

Top ten side effects of beta-blockers reported in the literature, and percentage of patients who discontinue treatment due to side effects., Digestive bleeding linked to rupture of esophageal or gastric varices within three months of starting treatment., Biological and elastometric parameters measured before and after taking Carvedilol for three months.

Interventions

DRUGCARVEDILOL ARROW 6
DRUG25 mg

Sponsors

University Hospital Of Clermont-Ferrand
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Secondary

MeasureTime frame
Top ten side effects of beta-blockers reported in the literature, and percentage of patients who discontinue treatment due to side effects., Digestive bleeding linked to rupture of esophageal or gastric varices within three months of starting treatment., Biological and elastometric parameters measured before and after taking Carvedilol for three months.

Primary

MeasureTime frame
Hemodynamic response (binary efficacy criterion) at one month, defined by a decrease of at least 10% in the echo-endoscopic portosystemic gradient compared to the baseline value measured at inclusion.

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026